ALLMedicine™ Behçet Disease Center
Research & Reviews 227 results
Medicine Wang CR, Wong TW et. al.
Apr 28th, 2022 - Although single-cytokine inhibitors can be considered in treating severe or refractory Behçet disease (BD), these biologic agents are associated with potential therapeutic failure due to the multi-cytokine pathogenesis involving Th1- and Th17-type...
Mar 28th, 2022 - Background Knee pain and stiffness can be debilitating and difficult to treat. Lifestyle-limiting knee conditions may negatively affect body image and emotional well-being. Weight management, exercises/strengthening programs, physical therapy, phy...
Rheumatology (Oxford, England); Ion IM, Villessot M et. al.
Mar 26th, 2022 - Tumefactive lesion revealing neuro-Behçet disease.|2022|Ion IM,Villessot M,Goulabchand R,Cagnazzo F,Thouvenot E,|
American Journal of Ophthalmology; Maalouf G, Andrillon A et. al.
Feb 17th, 2022 - To compare the relapse rate of sight-threatening noninfectious uveitis (NIU) in patients treated with infliximab (IFX) or adalimumab (ADA). Observational retrospective multicenter study. A total of 330 patients (median age, 36 years; interquartile...
Clinical Rheumatology; Amin MM, Abdel Latif OM
Feb 8th, 2022 - Behçet's syndrome (BS) is a multi-systemic vasculitis characterized by recurrent oral ulcers, genital ulcers, ocular lesions, and other systemic manifestations. As there is no laboratory diagnostics of BS, the diagnosis is mainly clinical. To inve...
Guidelines 1 results
Annals of the Rheumatic Diseases; Hatemi G, Silman A et. al.
Feb 5th, 2008 - To develop evidence-based European League Against Rheumatism (EULAR) recommendations for the management of Behçet disease (BD) supplemented where necessary by expert opinion. The multidisciplinary expert committee, a task force of the EULAR Standi...
Clinicaltrials.gov 1 results
Dec 3rd, 2021 - Behçet's disease (BD) was first described by Turkish dermatologist Hulusi Behçet in 1937 as a triad of recurrent oral aphthae, genital ulcerations and relapsing uveitis (1). Behçet disease (BD) is an inflammatory vasculopathy with multisystemic in...
News 7 results
Jan 6th, 2020 - Drug Approvals for Rare Dermatologic Diseases On July 19, 2019, apremilast, a phosphodiesterase 4 inhibitor, became the first medication approved by the FDA for the treatment of adults with oral ulcers due to Behçet disease, a rare multisystem inf.
Oct 28th, 2019 - Knee pain and stiffness can be debilitating and difficult to treat. Lifestyle-limiting knee conditions may negatively affect body image and emotional well-being. Weight management, exercise/strengthening programs, physical therapy, physical modali...
Jul 8th, 2014 - Evaluation and Management Evaluation of the patient with AION should include the following: Complete history and eye examination; Pupils and ophthalmoscopy; Color vision and Amsler grid; Visual field testing; Lab tests: immediate erythrocyte sedim...
Jun 19th, 2014 - Long-term Outcome of Neuro-Behçet's Disease Noel N, Bernard R, Wechsler B, et al Arthritis Rheumatol. 2014;66:1306-1314 Study Summary Behçet disease (BD) is a rare form of vasculitis largely affecting men in the Mediterranean, Middle East, and Far...
Oct 4th, 2012 - Immunosuppressants Reduce Venous Thrombosis Relapse in Behçet's Disease Desbois AC, Wechsler B, Resche-Rigon M, et al Arthritis Rheum. 2012;64:2753-2760 Thrombosis in Behçet Disease Vascular thrombosis is known to be associated with Behçet disease...